|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Eifel PJ, Winter K, Morris M, Levenback C,
Grigsby PW, Cooper J, Rotman M, Gershenson D and Mutch DG: Pelvic
irradiation with concurrent chemotherapy versus pelvic and
para-aortic irradiation for high-risk cervical cancer: An update of
radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol.
22:872–880. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Stehman FB, Ali S, Keys HM, Muderspach LI,
Chafe WE, Gallup DG, Walker JL and Gersell D: Radiation therapy
with or without weekly cisplatin for bulky stage 1B cervical
carcinoma: Follow-up of a gynecologic oncology group trial. Am J
Obstet Gynecol. 197:503.e1–e6. 2007. View Article : Google Scholar
|
|
4
|
Zhao H, Li L, Su H, Lin B, Zhang X, Xue S,
Fei Z, Zhao L, Pan Q, Jin X and Xie C: Concurrent
paclitaxel/cisplatin chemoradiotherapy with or without
consolidation chemotherapy in high-risk early-stage cervical cancer
patients following radical hysterectomy: Preliminary results of a
phase III randomized study. Oncotarget. 7:70969–70978. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lea JS and Lin KY: Cervical cancer. Obstet
Gynecol Clin North Am. 39:233–253. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chemoradiotherapy for Cervical Cancer
Meta-Analysis Collaboration, . Reducing uncertainties about the
effects of chemoradiotherapy for cervical cancer: A systematic
review and meta-analysis of individual patient data from 18
randomized trials. J Clin Oncol. 26:5802–5812. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Sturdza A, Pötter R, Fokdal LU, Haie-Meder
C, Tan LT, Mazeron R, Petric P, Šegedin B, Jurgenliemk-Schulz IM,
Nomden C, et al: Image guided brachytherapy in locally advanced
cervical cancer: Improved pelvic control and survival in
RetroEMBRACE, a multicenter cohort study. Radiother Oncol.
120:428–433. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ishida M, Iwai Y, Tanaka Y, Okazaki T,
Freeman GJ, Minato N and Honjo T: Differential expression of PD-L1
and PD-L2, ligands for an inhibitory receptor PD-1, in the cells of
lymphohematopoietic tissues. Immunol Lett. 84:57–62. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yamazaki T, Akiba H, Iwai H, Matsuda H,
Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, et al:
Expression of programmed death 1 ligands by murine T cells and APC.
J Immunol. 169:5538–5545. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Iwai Y, Ishida M, Tanaka Y, Okazaki T,
Honjo T and Minato N: Involvement of PD-L1 on tumor cells in the
escape from host immune system and tumor immunotherapy by PD-L1
blockade. Proc Natl Acad Sci USA. 99:12293–12297. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Sharma P and Allison JP: The future of
immune checkpoint therapy. Science. 348:56–61. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang Q, Liu F and Liu L: Prognostic
significance of PD-L1 in solid tumor: An updated meta-analysis.
Medicine. 96:e63692017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen H, Xia B, Zheng T and Lou G:
Immunoscore system combining CD8 and PD-1/PD-L1: A novel approach
that predicts the clinical outcomes for cervical cancer. Int J Biol
Markers. 35:65–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tsuchiya T, Someya M, Takada Y, Hasegawa
T, Kitagawa M, Fukushima Y, Gocho T, Hori M, Nakata K, Hirohashi Y,
et al: Association between radiotherapy-induced alteration of
programmed death ligand 1 and survival in patients with uterine
cervical cancer undergoing preoperative radiotherapy. Strahlenther
Onkol. 196:725–735. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Miyasaka Y, Yoshimoto Y, Murata K, Noda
SE, Ando K, Ebara T, Okonogi N, Kaminuma T, Yamada S, Ikota H, et
al: Treatment outcomes of patients with adenocarcinoma of the
uterine cervix after definitive radiotherapy and the prognostic
impact of tumor-infiltrating CD8+ lymphocytes in pre-treatment
biopsy specimens: A multi-institutional retrospective study. J
Radiat Res. 61:275–284. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Karim R, Jordanova ES, Piersma SJ, Kenter
GG, Chen L, Boer JM, Melief CJ and van der Burg SH: Tumor-expressed
B7-H1 and B7-DC in relation to PD-1+ T-cell infiltration and
survival of patients with cervical carcinoma. Clin Cancer Res.
15:6341–6347. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Enwere EK, Kornaga EN, Dean M, Koulis TA,
Phan T, Kalantarian M, Köbel M, Ghatage P, Magliocco AM,
Lees-Miller SP and Doll CM: Expression of PD-L1 and presence of
CD8-positive T cells in pre-treatment specimens of locally advanced
cervical cancer. Mod Pathol. 30:577–586. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Gu X, Dong M, Liu Z, Mi Y, Yang J, Zhang
Z, Liu K, Jiang L, Zhang Y, Dong S and Shi Y: Elevated PD-L1
expression predicts poor survival outcomes in patients with
cervical cancer. Cancer Cell Int. 19:1462019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Carvalho HA and Villar RC: Radiotherapy
and immune response: The systemic effects of a local treatment.
Clinics (Sao Paulo). 73 (Suppl 1):e557s2018. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pecorelli S: Revised FIGO staging for
carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol
Obstet. 105:103–104. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Donnem T, Hald SM, Paulsen EE, Richardsen
E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M,
Poehl M, et al: Stromal CD8+ T-cell Density-A promising supplement
to TNM staging in non-small cell lung cancer. Clin Cancer Res.
21:2635–2643. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Feldmeyer L, Hudgens CW, Ray-Lyons G,
Nagarajan P, Aung PP, Curry JL, Torres-Cabala CA, Mino B,
Rodriguez-Canales J, Reuben A, et al: Density, distribution, and
composition of immune infiltrates correlate with survival in merkel
cell carcinoma. Clin Cancer Res. 22:5553–5563. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Teng F, Mu D, Meng X, Kong L, Zhu H, Liu
S, Zhang J and Yu J: Tumor infiltrating lymphocytes (TILs) before
and after neoadjuvant chemoradiotherapy and its clinical utility
for rectal cancer. Am J Cancer Res. 5:2064–2074. 2015.PubMed/NCBI
|
|
24
|
Arina A, Beckett M, Fernandez C, Zheng W,
Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, et al:
Tumor-reprogrammed resident T cells resist radiation to control
tumors. Nat Commun. 10:39592019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yoneda K, Kuwata T, Kanayama M, Mori M,
Kawanami T, Yatera K, Ohguri T, Hisaoka M, Nakayama T and Tanaka F:
Alteration in tumoural PD-L1 expression and stromal CD8-positive
tumour-infiltrating lymphocytes after concurrent chemo-radiotherapy
for non-small cell lung cancer. Br J Cancer. 121:490–496. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kelly RJ, Zaidi AH, Smith MA, Omstead AN,
Kosovec JE, Matsui D, Martin SA, DiCarlo C, Werts ED, Silverman JF,
et al: The dynamic and transient immune microenvironment in locally
advanced esophageal adenocarcinoma post chemoradiation. Ann Surg.
268:992–999. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen G and Emens LA: Chemoimmunotherapy:
Reengineering tumor immunity. Cancer Immunol Immunother.
62:203–216. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
van der Most RG, Currie AJ, Cleaver AL,
Salmons J, Nowak AK, Mahendran S, Larma I, Prosser A, Robinson BW,
Smyth MJ, et al: Cyclophosphamide chemotherapy sensitizes tumor
cells to TRAIL-dependent CD8 T cell-mediated immune attack
resulting in suppression of tumor growth. PLoS One. 4:e69822009.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kodumudi KN, Woan K, Gilvary DL, Sahakian
E, Wei S and Djeu JY: A novel chemoimmunomodulating property of
docetaxel: Suppression of myeloid-derived suppressor cells in tumor
bearers. Clin Cancer Res. 16:4583–4594. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shinto E, Hase K, Hashiguchi Y, Sekizawa
A, Ueno H, Shikina A, Kajiwara Y, Kobayashi H, Ishiguro M and
Yamamoto J: CD8+ and FOXP3+ tumor-infiltrating T cells before and
after chemoradiotherapy for rectal cancer. Ann Surg Oncol. 21
(Suppl 3):S414–S421. 2014. View Article : Google Scholar
|
|
31
|
Yoshimoto Y, Suzuki Y, Mimura K, Ando K,
Oike T, Sato H, Okonogi N, Maruyama T, Izawa S, Noda SE, et al:
Radiotherapy-induced anti-tumor immunity contributes to the
therapeutic efficacy of irradiation and can be augmented by CTLA-4
blockade in a mouse model. PLoS One. 9:e925722014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Walle T, Martinez Monge R, Cerwenka A,
Ajona D, Melero I and Lecanda F: Radiation effects on antitumor
immune responses: Current perspectives and challenges. Ther Adv Med
Oncol. 10:17588340177425752018. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sato H, Niimi A, Yasuhara T, Permata TBM,
Hagiwara Y, Isono M, Nuryadi E, Sekine R, Oike T, Kakoti S, et al:
DNA double-strand break repair pathway regulates PD-L1 expression
in cancer cells. Nat Commun. 8:17512017. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Topalian SL, Taube JM, Anders RA and
Pardoll DM: Mechanism-driven biomarkers to guide immune checkpoint
blockade in cancer therapy. Nat Rev Cancer. 16:275–287. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sindoni A, Minutoli F, Ascenti G and
Pergolizzi S: Combination of immune checkpoint inhibitors and
radiotherapy: Review of the literature. Crit Rev Oncol Hematol.
113:63–70. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Karam SD and Raben D: Radioimmunotherapy
for the treatment of head and neck cancer. Lancet Oncol.
20:e404–e416. 2019. View Article : Google Scholar
|
|
37
|
Sato H, Okonogi N and Nakano T: Rationale
of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy
for cancer treatment. Int J Clin Oncol. 25:801–809. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Morris M, Eifel PJ, Lu J, Grigsby PW,
Levenback C, Stevens RE, Rotman M, Gershenson DM and Mutch DG:
Pelvic radiation with concurrent chemotherapy compared with pelvic
and para-aortic radiation for high-risk cervical cancer. N Engl J
Med. 340:1137–1143. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Rose PG, Bundy BN, Watkins EB, Thigpen JT,
Deppe G, Maiman MA, Clarke-Pearson DL and Insalaco S: Concurrent
cisplatin-based radiotherapy and chemotherapy for locally advanced
cervical cancer. N Engl J Med. 340:1144–1153. 1999. View Article : Google Scholar : PubMed/NCBI
|
